Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Guggenheim to Hold

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) was downgraded by Guggenheim from a "strong-buy" rating to a "hold" rating in a research report issued on Thursday, May 22nd, MarketBeat Ratings reports.

A number of other analysts have also recently weighed in on VIGL. Citizens Jmp cut Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Jefferies Financial Group cut Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. Wedbush cut Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and reduced their price target for the company from $13.00 to $8.00 in a report on Thursday, May 22nd. HC Wainwright reduced their price target on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a report on Friday, March 14th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Ten equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $10.80.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock traded down $0.01 during mid-day trading on Thursday, reaching $7.89. 578,762 shares of the company were exchanged, compared to its average volume of 1,105,196. Vigil Neuroscience has a twelve month low of $1.31 and a twelve month high of $7.95. The firm's 50-day simple moving average is $2.55 and its two-hundred day simple moving average is $2.39. The firm has a market cap of $368.01 million, a PE ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. As a group, equities research analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BVF Inc. IL increased its position in Vigil Neuroscience by 121.3% during the first quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock worth $7,144,000 after buying an additional 2,200,000 shares during the last quarter. Aberdeen Group plc lifted its stake in Vigil Neuroscience by 226.3% during the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock worth $3,070,000 after purchasing an additional 1,196,048 shares during the last quarter. Blair William & Co. IL lifted its stake in Vigil Neuroscience by 219.1% during the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock worth $1,840,000 after purchasing an additional 709,677 shares during the last quarter. Woodline Partners LP lifted its stake in Vigil Neuroscience by 239.1% during the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company's stock worth $831,000 after purchasing an additional 344,614 shares during the last quarter. Finally, 683 Capital Management LLC lifted its stake in shares of Vigil Neuroscience by 24.3% in the 1st quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock valued at $3,097,000 after acquiring an additional 340,000 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.